HIV patients may ditch daily injections for a pill
NCT ID NCT00454337
First seen Apr 07, 2026 · Last updated May 22, 2026 · Updated 8 times
Summary
This study looked at whether people with HIV who were already well-controlled on a regimen including enfuvirtide (an injectable drug) could safely switch to raltegravir (a pill). 170 participants were randomly assigned to either stay on enfuvirtide or switch to raltegravir. The main goal was to see if the switch was just as good at keeping the virus suppressed for 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Service des maladies infectieuses et tropicales Hopital Saint Louis
Paris, 75010, France
Conditions
Explore the condition pages connected to this study.